-
Mashup Score: 21Multidisciplinary Tumor Board Mucinous Ovarian Neoplasms - 6 month(s) ago
Multidisciplinary Tumor Board Mucinous Ovarian Neoplasms On behalf of Memorial Sloan Kettering Cancer Center (MSK), our India Center team invites you to MSK’s next international gynecologic oncology tumor board scheduled for Friday, 10 November 2023.Gynecological cancers are the leading causes of cancer morbidity and mortality for women in India. To share expertise, advance research, and improve…
Source: in.mskcc.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Multidisciplinary Tumor Board - Unraveling the Challenges: Comprehensive Approach to Management of CNS Metastases in Breast Cancer - 7 month(s) ago
Memorial Sloan Kettering Cancer Center (MSK) in New York proudly presents educational programs for current and future physicians and scientists. Through this interactive series, we look to accelerate the exchange of knowledge to improve patient outcomes, foster new research collaborations, and increase graduate and post-graduate training exchange. The focus of our next event will be on the management of oligoprogression in breast cancer. Wednesday, 11 October, 2023 6:00-7:30 p.m. IST | 8:30-10:00 a.m. US
Source: c.mskinfo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
On 10/11, @MSKCancerCenter & @aiims_newdelhi will launch a virtual tumor board series on #breast cancers. Join us in fighting cancer through patient care, education, research, & advocacy. Register here: https://t.co/0KlFMSnXJk #BCAM #tumorboard https://t.co/bM071hqR27
-
-
Mashup Score: 0
This survey study assesses use of American Head and Neck Society Virtual Tumor Board videos as a virtual learning for head and neck surgical oncology trainees.
Source: jamanetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In @JAMAOto an @AHNSinfo article, "Virtual Tumor Boards for Remote Learning in Head and Neck Surgical Oncology" 🔗: https://t.co/n44Y8rQSzn #Virtual #tumorboard #headandneck #surgical #oncology #educationalgrowth #Science #learning
-
-
Mashup Score: 0
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 66 year old man with a history of hypertension and hypercholesterolemia is presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Heather Jacene,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#TumorBoard Reviewing the Use of PSMA PET in Patients with Gleason 3+4=7 with MLH1 Pathogenic Mutation #Prostate Adenocarcinoma @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/lVAB5OcsBd @DanaFarber @LantheusNews @Progenics https://t.co/efGZ3MO2sN
-
-
Mashup Score: 0
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 62-year-old man with a history of hypertension. In November of 2021, the patient had a PSA test that was notable for being 57.58. In January, the patient came in for a biopsy Gleason 4+4=8, grade group 4. Prostate adenocarcinoma was identified in 12 of 12 cores. In February of 2022,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#TumorBoard reviewing the use of PSMA PET in #ProstateCancer - Gleason 4+4=8 GG 4, 12 of 12 Cores, high-risk localized disease. @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/jbTxAKFa47 @DanaFarber @LantheusNews @Progenics https://t.co/xxvH06hvDn
-
-
Mashup Score: 0
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 72-year-old male with no past medical history is presented. He has been followed for some time at this point. His PSA in December 2021 was 8.44. His repeat PSA in Feb 2022 was 7.61 and his DRE was notable for having a left-sided firm nodule. His prostate biopsy in March of 2022, was…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#TumorBoard reviewing the use of PSMA PET in patients with Gleason 4+5=9, GG 5 disease, bone scan demonstrated mild uptake #ProstateCancer with @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/CJ6BHmNEfV @DanaFarber @LantheusNews @Progenics https://t.co/o7o3FhuLyI
-
-
Mashup Score: 0Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6 - 10 month(s) ago
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 64 year old man with a history of kidney stones presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Heather Jacene, MD, Clinical Director of…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#TumorBoard Reviewing the Use of PSMA PET in the Care of Patients Who Underwent Fluciclovine for #ProstateCancer @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/PJzt2niIwd @DanaFarber @LantheusNews @Progenics https://t.co/i22xoOetOy
-
-
Mashup Score: 0
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 64-year-old man with a history of diabetes came into his local urologist with concerns of irritation on voiding for nine months despite treatment. In March of 2022, he had a PSA of 67.8 and in April he still had an elevated PSA of 56.4. In April, he also had an MRI that showed…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#TumorBoard Reviewing the Use of PSMA PET in #ProstateCancer Gleason 4+4=8 GG 4, PI-RADS 5 Lesion, Possible Seminal Vesicle Involvement with @HJacene, @adamkibel_uro, @DrPaulNguyen, and @CaPsurvivorship > https://t.co/KkONUXnVKd @DanaFarber @LantheusNews @Progenics https://t.co/SHibflwAj6
-
-
Mashup Score: 0
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 69-year-old man with a history of Crohn’s disease that’s under control, arthritis, chronic HCV, hypertension, and non-muscle-invasive bladder cancer is presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
#TumorBoard Reviewing the Use of PSMA PET in the Care of Patients with Gleason 3+4=7 GG 2, 3 Cores on Right, 6 Negative Cores #Prostate Adenocarcinoma @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/g4lc3J6EZk @DanaFarber @LantheusNews @Progenics https://t.co/95KiCZlVYh
-
-
Mashup Score: 0Tumor Board Reviewing the Use of PSMA PET in the Care of Patient Who Underwent Fluciclovine for Prostate Cancer - Session 1 Case 6 - 11 month(s) ago
In this Clinical Case-Based Learning Educational Program, a Virtual Tumor Board in Prostate Cancer, a case of a 64 year old man with a history of kidney stones presented, evaluated, and his treatment plan addressed. Independent Medical Education Initiative Supported by Progenics Pharmaceuticals, Inc. a subsidiary of Lantheus Holdings, Inc. Biographies: Heather Jacene, MD, Clinical Director of…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
#TumorBoard Reviewing the Use of PSMA PET in the Care of Patients Who Underwent Fluciclovine for #ProstateCancer @HJacene @adamkibel_uro @DrPaulNguyen & @CaPsurvivorship > https://t.co/PJzt2niIwd @DanaFarber @LantheusNews @Progenics https://t.co/9bPmfO82ig
-
On 11/10, @MSKCancerCenter & Regional Cancer Centre Thiruvananthapuram will host an international gynecological #tumorboard on Mucinous Ovarian Neoplasms. Register now: https://t.co/ZM9poddnlc https://t.co/0jSaoa95Sv